Key result
Preparticipation CV screening in young athletes remains controversial regarding efficacy, cost-effectiveness, and false positives.
Why the study?
Does preparticipation screening for cardiovascular abnormalities prevent sudden cardiac death in young competitive athletes?
Does preparticipation screening for cardiovascular abnormalities prevent sudden cardiac death in young competitive athletes?
This review provides an overview of preparticipation cardiovascular screening in young athletes to prevent sudden cardiac death, addressing controversies regarding efficacy, cost-effectiveness, and false-positive tests.
No takes yet. Share an insight, caveat, or question.
Screening decisions in young athletes warrant individualized caution; leaves open the need for definitive RCTs on SCD prevention.
Papadakis et al. (2008) conducted a review in Cardiovascular abnormalities in young competitive athletes. Preparticipation screening was evaluated. Preparticipation screening for cardiovascular abnormalities in young athletes (≤35 years) remains controversial regarding its efficacy, cost-effectiveness, and the impact of false-positive tests.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: